CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
五重难治性多发性骨髓瘤患者接受或不接受 BCMA 靶向治疗的结果
英文原题：Outcomes of Penta-Refractory Multiple Myeloma Patients Treated with or without BCMA-Directed Therapy.
查看英文原题
Outcomes of Penta-Refractory Multiple Myeloma Patients Treated with or without BCMA-Directed Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管治疗取得了进展，五重难治性多发性骨髓瘤（RRMM）患者的结局仍然很差。在这项回顾性分析中，我们评估了接受BCMA靶向治疗（BDT）的五重RRMM患者的生存结局。
我们识别了78例五重RRMM患者。中位年龄为65岁，29例（37%）患有R-ISS III期疾病，63例（81%）具有高危细胞遗传学，45例（58%）患有髓外疾病。五重难治状态前的中位LOT为5（3-12）。在五重RRMM患者中，43例（55%）接受了BDT治疗，35例（45%）未接受BDT治疗。接受的BDT类型包括belantamab mafadotin 15例（35%）、CAR-T 细胞疗法9例（21%）、BCMA单克隆抗体6例（14%）和双特异性T细胞衔接器2例（5%）。11例（25%）患者接受了超过一种BDT。两组之间的基线特征未发现显著差异。接受BDT治疗的患者中位总生存期更好，17 vs. 6个月，HR 0.3，p值< 0.001。较差的功能状态、白人种族和高危细胞遗传学与更差的结局相关，而使用BDT与更好的结局相关。五重难治性MM患者结局较差。
我们的回顾性分析显示，对于五重RRMM患者，与未使用BDT相比，使用BDT具有显著的生存获益。
展开英文摘要原文
Despite advances in treatment, outcomes remain poor for patients with penta-relapsed refractory multiple myeloma (RRMM). In this retrospective analysis, we evaluated the survival outcomes of penta-RRMM patients treated with (BCMA)- directed therapy (BDT).
We identified 78 patients with penta-RRMM. Median age was 65 years, 29 (37%) had R-ISS stage III disease, 63 (81%) had high-risk cytogenetics, and 45 (58%) had extra-medullary disease. Median LOT prior to penta-refractory state was 5 (3-12). Amongst penta-RRMM, 43 (55%) were treated with BDT, 35 (45%) were not treated with BDT. Type of BDT received included belantamab mafadotin 15 (35%), Chimeric Antigen Receptor T-cell therapy 9 (21%), BCMA monoclonal antibody 6 (14%), and Bispecific T-cell engager 2 (5%).
Eleven (25%) patients received more than one BDT. No significant differences were identified between baseline characteristics for the two groups. Patients treated with a BDT had better median overall survival, 17 vs. 6 months, HR 0. 3 p -value < 0. 001. Poor performance status, white race, and high-risk cytogenetics were associated with worse outcomes, whereas using a BDT was associated with better outcomes. Patients with penta-refractory MM have poor outcomes.
Our retrospective analysis showed a significant survival benefit using BDT when compared to non-BDT for patients with penta-RRMM.
论文信息
- 作者
- Atrash S、Mammadzadeh A、Peng F、Alkharabsheh O、Afrough A、Cui W、Mahmoudjafari Z、Abdallah AO
- 第一作者单位
- Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC 28204, USA.United States
- 通讯作者单位
- US Myeloma Research Innovations Research Collaborative (USMIRC), Westwood, KS 66205, USA.United States
- 期刊
- Cancers2023 May 24
- 原文标识
- PubMed 37296856 · DOI 10.3390/cancers15112891
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →